Senate Proposal Aims to Fortify Generic Drug Makers with ‘Skinny Labels’ Protection

A bipartisan coalition of senators from Colorado, Arkansas, Vermont, and Maine has put forth a legislative initiative aimed at protecting generic-drug and biosimilar manufacturers. This proposed bill seeks to shield these manufacturers from infringement liability when they employ the use of “skinny labels,” which are narrower versions of FDA-approved labeling designed to avoid patent infringement on brand-name drugs. By doing so, the bill addresses a significant legal challenge faced by generic and biosimilar makers. For further details on this legislative effort, you can read more on the Law360 website.